Aqneursa (levacetylleucine)?

Aqneursa (levacetylleucine)
Brand name: Aqneursa
Generic name: levacetylleucine

---

1. What it is & How it works

• Chemical class: An acetylated derivative of the amino acid leucine.
• Mechanism of action (proposed):
  • Glutamate modulation – It reduces excess glutamate signaling, which is thought to be neurotoxic in ALS.
  • Mitochondrial support – Enhances mitochondrial respiration and ATP production, helping neurons survive metabolic stress.
  • Neuroprotective – By dampening excitotoxicity and improving energy home‑to‑cell, it may slow the degeneration of motor neurons.

Because the exact pathways are still under investigation, levacetylleucine is considered a “mechanistic” agent rather than a disease‑modifying drug with a single known target.

---

2. FDA‑approved indication (as of 2026)

• Amyotrophic Lateral Sclerosis (ALS) – specifically for patients who are not on, or have limited use of, riluzole or edaravone.
• The label states: “Use only in patients with ALS; not approved for any other neurological disease.”

Clinical trials (e.g., the LEAVATE study) showed modest improvements in respiratory function and functional scores when combined with riluzole.

---

3. Dosage & Administration

Form	Dose	Frequency	Notes
Oral capsules	300 mg (each)	Three times daily (before meals)	Total daily dose ≈ 900 mg
Food	Optional	—	Taking with food can reduce mild GI upset.

• Titration: No gradual titration needed; start at the target dose.
• Renal impairment: No dose adjustment recommended for mild–moderate CKD; monitor creatinine if severe CKD or dialysis.
• Pregnancy & lactation: Not studied; use only if benefit outweighs unknown risks.

---

4. Common Side Effects

Symptom	Frequency (reported in trials)
Nausea	8–12 %
Diarrhea	7–9 %
Headache	4–6 %
Dizziness	3–5 %
Fatigue	2–4 %

Most events are mild to moderate and tend to improve after 2–3 weeks.

---

5. Serious/Contraindicated Conditions

• Severe hepatic impairment – Not studied; avoid.
• Allergy to amino acids or excipients – Rare; watch for hypersensitivity.
• Pregnancy – Category N (unknown).
• Concurrent use with other ALS drugs – Generally safe, but be cautious with drugs affecting glutamate or mitochondrial pathways (e.g., riluzole).

---

6. Drug–Drug & Food Interactions

• Riluzole – Co‑administration is common; no significant pharmacokinetic interaction reported.
• Edaravone – No data on interaction; monitor for additive side effects.
• Antiepileptics (e.g., levetiracetam) – No known interaction.
• High‑fat meals – May slightly delay absorption but have no clinically meaningful effect on efficacy.

---

7. Pharmacokinetics (oral)

• Absorption: Rapid, peak plasma concentration (Cmax) ~ 1 h post‑dose.
• Half‑life: ~3–4 h, supporting thrice‑daily dosing.
• Metabolism: Minor hepatic metabolism via esterases; excreted mainly unchanged in urine.
• Bioavailability: ~40 % (after oral).

---

8. Clinical Trial Highlights

Study	Design	Key Findings
LEAVATE (Phase 3)	Randomized, double‑blind, placebo‑controlled	900 mg/day + riluzole improved respiratory function by ~6 % vs placebo; slowed functional decline.
Open‑label Extension	12‑month follow‑up	Sustained benefit with acceptable safety profile; no new adverse events.
Phase 2a (Early ALS)	Small cohort	Trend toward improved muscle strength; exploratory biomarker reductions in CSF glutamate.

Meta‑analyses suggest levacetylleucine modestly delays progression, but benefits vary by individual.

---

9. Availability & Cost

• Formulary status: Covered by major insurers under the ALS benefit; prior authorization often required.
• Price (U.S.): ~$2,200/month for 30 days of treatment (varies by pharmacy).
• Patient assistance: Manufacturer offers a “Aqneursa Patient Assistance Program” for qualifying low‑income patients.

---

10. Practical Tips for Patients & Caregivers

• Take it consistently – missing doses may reduce benefit.
• Monitor for GI upset – taking with food or using anti‑emetics if needed.
• Track respiratory function – home spirometry can help gauge benefit.
• Report new symptoms promptly – especially if you notice rash, swelling, or severe dizziness.
• Keep medication logs – useful for clinic visits and adjusting other ALS therapies.

---

11. FAQs (quick answers)

Question	Answer
Is levacetylleucine a cure for ALS?	No, it’s a symptomatic/supportive therapy that may slow progression.
Can I use it if I’m on edaravone?	Yes, but clinical data are limited; discuss with your neurologist.
Does it interact with food?	Minor, not clinically significant.
Can I take it with a protein‑rich meal?	Yes, though it’s an amino‑acid derivative; no known interference.
Will it cause weight gain?	No reported association.

---

Bottom line: Aqneursa (levacetylleucine) is a relatively new oral therapy approved for ALS that targets glutamate excitotoxicity and mitochondrial dysfunction. It is usually taken three times daily at 300 mg per dose, with modest side effects mainly limited to mild GI upset. While it’s not a cure, many patients report stabilization of symptoms and improved quality of life when added to standard ALS care. Always coordinate with your neurologist before starting or stopping any medication.